Valvular & structural heart disease
Early outcomes of off-label transcatheter tricuspid valve repair/replacement in the STS/ACC transcatheter valve therapies (TVT) registry
Authors' conclusion
Off-label use of transcatheter tricuspid valve interventions was highly variable across institutions, with the majority of institutions performing <5 procedures, while others performed >100. Both T-TEER and TTVR reduced residual TR to ≤ moderate in the majority of cases and were associated with substantial improvements in quality of life.
Study context
- Population
- Patients undergoing isolated commercial, off-label transcatheter tricuspid valve replacement (TTVR) or T-TEER for tricuspid regurgitation (TR) without stenosis in the STS/ACC TVT registrytricuspid procedures at 142 sites from January, 2021 to December, 2023
- Participants
- 995 tricuspid procedures
- Exposure
- TTVR vs T-TEER
- TTVRn = 238
- T-TEERn = 757
- Outcome
- Residual TR severity and change in KCCQ-OS
- Follow-up
- 30 days
Main finding
As reported in the abstract
≤ moderate residual TR
Substantial improvement in KCCQ-OS
Moderate improvement in KCCQ-OS
Observational data: associations, not effects.
Secondary outcomes
Mortality (30-day and 1-year estimated)
30-day mortality
1-year estimated mortality
Median age
| Outcome | TTVR | T-TEER |
|---|---|---|
| Median age | 60 | 78 |
Institutional volume
- Sites performing 5 or fewer procedures
- 72%
- 4 high-volume centers, procedures performed
- 49, 81, 94, and 120
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →